**Table A.1**: Baseline characteristics for individuals with severe mental disorders and CRP measurements (*n*=3,034).

|  | **CRP level, mg/L** | | | |
| --- | --- | --- | --- | --- |
| **Characteristics** | **<1 mg/L** | **1-3 mg/L** | **3-10 mg/L** | **>10 mg/L** |
| **No. (%)** | 504 (16.6) | 1,007 (33.2) | 1,006 (33.2) | 517 (17.0) |
|  |  |  |  |  |
| **Female, No. (%)**a | 296 (58.7) | 545 (54.1) | 651 (64.7) | 353 (68.3) |
| **Age at index diagnosis, median (IQR), y** | 35.4 (24.8-43.3) | 34.7 (25.5-43.2) | 35.4 (26.4-43.7) | 35.3 (26.8-43.8) |
| **Inpatient at index diagnosis, No. (%)**a | 218 (43.3) | 513 (50.9) | 523 (52.0) | 277 (53.6) |
| **Calendar year at index diagnosis, No. (%)**a |  |  |  |  |
| 2000-2004 | 73 (14.5) | 113 (11.2) | 106 (10.5) | 94 (18.2) |
| 2005-2009 | 179 (35.5) | 469 (46.6) | 520 (51.7) | 217 (42.0) |
| 2010-2012 | 252 (50.0) | 425 (42.2) | 380 (37.8) | 206 (39.8) |
| **Psychiatric contacts in the previous year** |  |  |  |  |
| Any contact, No. (%)a | 131 (26.0) | 331 (32.9) | 325 (32.3) | 193 (37.3) |
| Number of contacts, median (IQR) | 1 (1-3) | 2 (1-3) | 2 (1-3) | 2 (1-3) |
| Admitted more than 30 days, No. (%) | 15 (22.7) | 38 (23.3) | 54 (31.4) | 34 (31.8) |
| **Somatic contacts in the previous year** |  |  |  |  |
| Any contact, No. (%) | 345 (68.5) | 700 (69.5) | 718 (71.4) | 383 (74.1) |
| Number of contacts, median (IQR)a | 3 (2-5) | 3 (1-5) | 3 (2-7) | 3 (2-7) |
| Admitted more than 10 days, No. (%)a | 20 (10.1) | 33 (8.2) | 53 (12.9) | 51 (20.4) |
| **Any somatic comorbidity as defined by diseases from the Charlson comorbidity index, No. (%)**a | 59 (11.7) | 158 (15.7) | 218 (21.7) | 148 (28.6) |
| **Previous episodes of suicidal behaviour, No. (%)** | 126 (25.0) | 255 (25.3) | 249 (24.8) | 145 (28.1) |
| **In work, No. (%)** (*n*=2,527)a | 236 (57.4) | 495 (61.2) | 445 (51.5) | 198 (44.8) |
| **Primary education as the highest completed level, No. (%)** (*n*=2,982)a | 204 (41.1) | 442 (44.4) | 475 (48.3) | 241 (47.5) |
| **Married or cohabiting, No. (%)** (*n*=3,033) | 260 (51.6) | 544 (54.1) | 508 (50.5) | 242 (46.8) |
| **Any use in the previous year, No. (%)** |  |  |  |  |
| Antipsychotica | 83 (16.5) | 237 (23.5) | 254 (25.3) | 154 (29.8) |
| Antidepressantsa | 335 (66.5) | 722 (71.7) | 782 (77.7) | 385 (74.5) |
| Benzodiazepinesa | 170 (33.7) | 362 (36.0) | 424 (42.2) | 224 (43.3) |
| Anti-inflammatorya | 118 (23.4) | 283 (28.1) | 324 (32.2) | 191 (36.9) |
| Corticosteroids | 20 (4.0) | 44 (4.4) | 42 (4.2) | 30 (5.8) |
| Analgesicsa | 85 (16.9) | 201 (20.0) | 238 (23.7) | 141 (27.3) |

a The distribution differed significantly between CRP levels (p<0.05).

**Table A.2**: Baseline characteristics for individuals with severe mental disorders and WBC measurements (*n*=4,855).

|  | **WBC level, x109/L** | | |
| --- | --- | --- | --- |
| **Characteristics** | **<4. 5x109/L** | **4.5-10x109/L** | **>10x109/L** |
| **No. (%)** | 273 (5.6) | 3,835 (79.0) | 747 (15.4) |
|  |  |  |  |
| **Female, No. (%)**a | 181 (66.3) | 2,241 (58.4) | 467 (62.5) |
| **Age at index diagnosis, median (IQR), y**a | 33.4 (25.3-43.1) | 34.1 (25.0-42.6) | 36.1 (27.5-43.7) |
| **Inpatient at index diagnosis, No. (%)** | 127 (46.5) | 1,932 (50.4) | 371 (49.7) |
| **Calendar year at index diagnosis, No. (%)**a |  |  |  |
| 2000-2004 | 42 (15.4) | 600 (15.7) | 144 (19.3) |
| 2005-2009 | 99 (36.3) | 1,620 (42.2) | 330 (44.2) |
| 2010-2012 | 132 (48.3) | 1,615 (42.1) | 273 (36.5) |
| **Psychiatric contacts in the previous year** |  |  |  |
| Any contact, No. (%) | 99 (36.3) | 1,278 (33.3) | 269 (36.0) |
| Number of contacts, median (IQR) | 2 (1-3) | 2 (1-3) | 2 (1-3) |
| Admitted more than 30 days, No. (%) | 17 (34.7) | 172 (27.7) | 40 (28.6) |
| **Somatic contacts in the previous year** |  |  |  |
| Any contact, No. (%)a | 172 (63.0) | 2,491 (65.0) | 547 (73.2) |
| Number of contacts, median (IQR) | 3 (1-5) | 3 (1-5) | 3 (2-5) |
| Admitted more than 10 days, No. (%)a | 16 (18.8) | 131 (10.1) | 40 (11.8) |
| **Any somatic comorbidity as defined by diseases from the Charlson comorbidity index, No. (%)**a | 51 (18.7) | 636 (16.6) | 153 (20.5) |
| **Previous episodes of suicidal behaviour, No. (%)**a | 41 (15.0) | 827 (21.6) | 239 (32.0) |
| **In work, No. (%)** (*n*=4,068) | 121 (55.8) | 1,792 (56.1) | 344 (52.2) |
| **Primary education as the highest completed level, No. (%)** (*n*=4,781)a | 78 (29.0) | 1,682 (44.5) | 360 (49.1) |
| **Married or cohabiting, No. (%)** (*n*=4,853) | 137 (50.2) | 1,928 (50.3) | 361 (48.3) |
| **Any use in the previous year, No. (%)** |  |  |  |
| Antipsychotic | 62 (22.7) | 880 (23.0) | 186 (24.9) |
| Antidepressants | 200 (73.3) | 2,726 (71.1) | 541 (72.4) |
| Benzodiazepinesa | 98 (35.9) | 1,403 (36.6) | 314 (42.0) |
| Anti-inflammatorya | 61 (22.3) | 1,014 (26.4) | 246 (32.9) |
| Corticosteroids | 6 (2.2) | 138 (3.6) | 38 (5.1) |
| Analgesicsa | 48 (17.6) | 735 (19.2) | 173 (23.2) |

a The distribution differed significantly between WBC levels (p<0.05).